Immutep Reports that LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy in Preclinical Studies
News Jun 27, 2008
Immutep S.A., a biopharmaceutical company specialized in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced the publication of research conducted by Cell Genesys, Inc. showing that a lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting tumor cell immunotherapy. These data were published in the June issue of Clinical Cancer Research.
The research team found that combining mLAG-3Ig with a murine GM-CSF-secreting tumor cell immunotherapy prolonged the survival of tumor-bearing animals compared to animals treated with either therapy alone.
Prolonged survival correlated with increased numbers of systemic IFN gamma-secreting CD8+ T-cells and a significantly increased infiltration of activated effector CD8+ T-cells into the tumor.
The mLAG-3Ig fusion protein is a murine homologue of Immutep's lead product ImmuFact® IMP321, a potent natural human immunostimulatory factor designed to amplify the T cell immune response.
IMP321 can be used either as an immunopotentiator in therapeutic vaccines or alone at higher doses as a monotherapy or in combination with chemotherapy. Six clinical trials have been initiated with ImmuFact IMP321 in the last three years.
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE